Call Us: 1.800.873.5297


Dangerous Drug, Chantix

Reports of erratic behavior and suicide have been associated with the use of Chantix, a drug that was designed to help people stop smoking and was approved by the Food and Drug Administration just under two years ago. In November 2007, the FDA issued a statement that they are reviewing the possible Chantix suicide side effects and that there have been over 100 reports received of suicidal thoughts and severe behavioral changes within just a few weeks of taking the drug.

Since its approval by the FDA, over 4 million Americans have received a prescription for the drug. Smoking is the leading preventable cause of disease and premature death in the United States and accounts for more than 400,000 deaths every year.

Because of these reports, defective product and dangerous drug attorneys are evaluating the potential of Chantix lawsuits on behalf of people who have committed suicide or suffered severe injury as a result of the drug’s adverse side effects.

Chantix (generic varenicline tartrate) was approved by the FDA in May 2006 as part of a review that drastically shortened the time required for the drug maker to begin selling the medication. Chantix helps people to quit smoking by easing the withdrawal symptoms of nicotine cessation and by blocking some of the effects of nicotine from cigarettes, which helps to promote long-term smoking cessation.

Label Update

When the FDA issued its November 2007 statement regarding Chantix and suicide, it requested data from the drug’s manufacturer, Pfizer, about reported problems involving suicide and aggressive or erratic behavior associated with the medication. On November 20, 2007, Pfizer updated Chantix’s label to indicate that the drug’s side effects include the following: “reports of depressed mood, agitation, changes in behavior, suicidal ideation and suicide in patients attempting to quit smoking while taking Chantix.”

Additionally, the FDA is reviewing reports that the drug could cause problems while driving or operating heavy machinery. While the number of these incidents is very small, the FDA pointed out that they all describe similar situations with symptoms of drowsiness leading to difficulty operating a vehicle.

Other reported side effects of Chantix include:

• Nausea
• Stomach pain
• Vomiting
• Indigestion
• Weakness
• Lethargy
• Increased appetite
• Unpleasant taste in your mouth
• Headache
• Insomnia
• Unusual dreams

If you or a loved one has taken Chantix and experienced suicidal thoughts or behavior, you may have valid legal claim. Please contact Schlichter, Bogard & Denton today to schedule a confidential consultation.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.